Teladoc bets $18.5bn that Covid-19 will change the world for good
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
Smaller device makers put in a muted performance
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
Poor fourth quarter mars strong year for medtech floats
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
Keeping corporations healthy is good business for Livongo
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
Livongo enters the medtech float hall of fame
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
$100m venture rounds become standard for device makers
The first quarter of this year saw more venture funding raised by medical device groups than any other period since 2010.